As of January 12, 2026, a new clinical trial is spotlighting immunoadsorption therapy as a novel medical device intervention for Autoimmune Long COVID. The study is currently recruiting, offering fresh hope for individuals affected by persistent post-COVID-19 conditions.
What changed?
Long COVID, a condition with symptoms persisting long after acute COVID-19 infection, continues to challenge healthcare providers and patients alike. A new clinical trial, led by the Academisch Medisch Centrum – Universiteit van Amsterdam (AMC-UvA), aims to evaluate the effectiveness of immunoadsorption therapy as a medical device intervention for treating autoimmune forms of Long COVID.
The trial distinguishes itself by examining the role of immunoadsorption, a specialized technology for filtering antibodies from the bloodstream. Recruitment is actively underway for eligible participants, signaling an important step in the exploration of innovative therapies for this challenging condition.
What is immunoadsorption, and how does it work?
Immunoadsorption is a device-based therapy designed to selectively remove harmful antibodies from the bloodstream. This process may reduce the immune-mediated damage associated with autoimmune conditions. The device functions through a filtration system that targets specific immunoglobulins while preserving beneficial blood components.
In the context of Long COVID, the intervention focuses on mitigating autoimmune-driven complications, potentially improving patients’ quality of life. A comparator arm involving a sham device aims to validate the observed outcomes.
Who benefits from this study?
The trial targets individuals with autoimmune manifestations of Long COVID, also referred to as Long COVID-19 Syndrome or Post COVID Syndrome. Symptoms often include persistent fatigue, brain fog, joint pain, and other debilitating issues. By addressing autoimmunity in this subset of individuals, the study seeks to uncover specific avenues for treatment.
Participants are screened based on defined eligibility criteria to ensure the intervention’s applicability to their condition. The trial aims to provide meaningful data that could shape future therapeutic approaches.
Details on the ongoing clinical trial
The clinical study, sponsored by AMC-UvA, involves two main arms:
- Intervention Group: Participants treated with the immunoadsorption device.
- Control Group: Participants exposed to a sham comparator to establish a baseline for efficacy evaluation.
The trial emphasizes safety and performance as required by regulatory standards, aligning with MDR Annex XIV provisions. The sponsor is responsible for oversight and adherence to clinical and ethical guidelines throughout the trial duration.
For more details, interested parties can refer to the official trial listing linked at the end of this article.
Frequently Asked Questions
- What is the aim of this trial?
To evaluate the safety and effectiveness of immunoadsorption therapy for autoimmune Long COVID symptoms. - Is the trial randomized?
Yes, the study includes both an intervention group and a sham comparator group to ensure robust data. - Where is the trial being conducted?
The trial is led by AMC-UvA in Amsterdam and may involve other centers; consult the study listing for details.
Conclusion
The ongoing evaluation of immunoadsorption therapy brings renewed attention to device-based interventions for Long COVID. By addressing underlying autoimmune pathways, this clinical trial has the potential to expand therapeutic options for post-COVID-19 conditions. Clinicians, regulatory stakeholders, and patients alike can monitor developments with optimism.
Disclaimer
This article is for informational purposes only. It does not provide legal or medical advice. Readers should consult qualified professionals for specific concerns.
Further details and full trial listing
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07316127?term=medical+device